Amplified in tumors

Articles

• REL
  9 January 2007

  c-rel

• TNFSF13B
  8 March 2006

  BAFF, BLYS, TALL1, THANK

• PPM1D
  19 May 2008

  Pathology
  PPM1D is an oncogene that is amplified and overexpressed in many human tumors, including breast cancer.
  It functions as a negative regulator of the p38 MAP kinase-p53 signaling pathway and is also proposed to participate in other critical cell survival pathways.
  PPM1D is involved in the regulation of cell proliferation in breast cancer in a p53-dependent manner. Overexpression of PPM1D contributes to malignant phenotype by promoting sustained cell growth and cell survival. (...)

• CLDN12
  17 May 2008

  Definition: Claudins (CLDNs), such as CLDN12, are components of epithelial cell tight junctions.
  Tight junctions regulate movement of solutes and ions through the paracellular space and prevent mixing of proteins and lipids in the outer leaflet of the apical and basolateral plasma membrane domains.
  Pathology
  amplified in esophageal adenocarcinoma
  See also
  Claudins (CLDNs)

• EZH2
  23 January 2006

  Enhancer of zeste homolog 2 (EZH2) WKP
  Definition: Ezh2 is a polycomb group protein. EZH2 is known to function in histone methylation, thereby regulating gene expression.
  Ezh2-containing complex has been given an additional role in cellular regulation. Cytosolic Ezh2 methyltransferase complexes were shown to associate with Vav1 and control receptor-induced actin polymerization and proliferation in a methylation-dependent manner.
  Overall, lysine methylation is a posttranslational (...)

• YEATS4
  30 September 2008

  Definition: YEATS4 is a transcription factor.
  Shown to inhibit p53 transactivation activity and decrease the p53 proapoptotic response, the inhibition of YEATS4 results in p53 stabilization and activation.
  Pathology
  YEATS4 is a transcription factor amplified in human gliomas.
  YEATS4 (GAS41) as a novel oncogene important in the pathogenesis of WDLPS/DDLPS (well-differentiared liposarcoma/dedifferentiated liposarcoma).
  The functional impairment of the p53 pathway plays a crucial role (...)

• WNT5B
  18 January 2005

  Pathology
  association with type 2 diabetes (#15386214#)
  12p13 amplification in tumors pediatric malignant astrocytoma (#20068183#)
  References
  Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Cancer Res. 2010 Jan 15;70(2):512-9. PMID: (...)

• PDGFRA
  12 December 2003

  platelet-derived growth factor receptor (PDGFR) alpha, PDGFR-alpha

• DYRK2
  30 September 2008

  Human fetal brain DYRK2 (GenBank Y13493) cDNAs encode 2 isoforms: a deduced 528-amino acid protein and a protein containing 73 additional amino acids at the N terminus.
  The DYRK2 proteins contain a canonical kinase domain located between a large N-terminal region and a short C-terminal extension, and features specific to DYRK-related kinases.
  DYRK2 shares 46% identity with DYRK1 in the catalytic domain, but lacks the striking sequence motifs identified in DYRK1.
  The DYRK2 and DYRK3 (...)

• IKBKE
  29 August 2008

  Pathology
  amplified by amp(1)(q32.1) in mammary carcinomas (breast cancer)

0 | 10 | 20